cholinergic antagonists

Summary

Summary: Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.

Top Publications

  1. pmc Treatment persistence and compliance with medications for chronic obstructive pulmonary disease
    Joyce A Cramer
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516 2770, USA
    Can Respir J 14:25-9. 2007
  2. ncbi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
  3. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
  4. ncbi Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study
    Chris Fox
    Department of Psychiatry, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    J Am Geriatr Soc 59:1477-83. 2011
  5. ncbi A drug burden index to define the functional burden of medications in older people
    Sarah N Hilmer
    Laboratory of Clinical Investigation and Clinical Research Branch, Intramural Research Program, National Institute on Aging, Baltimore and Bethesda, MD, USA
    Arch Intern Med 167:781-7. 2007
  6. ncbi Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease
    Bartolome Celli
    Brigham and Women s Hospital and St Elizabeth s Medical Center, Boston, MA 02115, USA
    Am J Respir Crit Care Med 180:948-55. 2009
  7. pmc Use of anticholinergics and the risk of cognitive impairment in an African American population
    N L Campbell
    Wishard Health Services, Indianapolis, IN 46202 2872, USA
    Neurology 75:152-9. 2010
  8. ncbi Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial
    T Troosters
    Respiratory Division and Pulmonary Rehabilitation, UZ Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium
    Eur Respir J 36:65-73. 2010
  9. pmc The cognitive impact of anticholinergics: a clinical review
    Noll Campbell
    Wishard Health Services, Indianapolis, IN, USA
    Clin Interv Aging 4:225-33. 2009
  10. ncbi Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
    D E O'Donnell
    Respiratory Investigation Unit, Dept of Medicine, Queen s University, Kingston, Ontario, Canada
    Eur Respir J 23:832-40. 2004

Research Grants

Detail Information

Publications209 found, 100 shown here

  1. pmc Treatment persistence and compliance with medications for chronic obstructive pulmonary disease
    Joyce A Cramer
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516 2770, USA
    Can Respir J 14:25-9. 2007
    ..The present study assessed the patterns of persistence with the above mentioned inhaled medications...
  2. ncbi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
    ..Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy...
  3. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  4. ncbi Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study
    Chris Fox
    Department of Psychiatry, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    J Am Geriatr Soc 59:1477-83. 2011
    ..To determine whether the use of medications with possible and definite anticholinergic activity increases the risk of cognitive impairment and mortality in older people and whether risk is cumulative...
  5. ncbi A drug burden index to define the functional burden of medications in older people
    Sarah N Hilmer
    Laboratory of Clinical Investigation and Clinical Research Branch, Intramural Research Program, National Institute on Aging, Baltimore and Bethesda, MD, USA
    Arch Intern Med 167:781-7. 2007
    ..We developed an index to determine drug burden based on pharmacologic principles. We evaluated the relationship of this index to physical and cognitive performance apart from disease indication...
  6. ncbi Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease
    Bartolome Celli
    Brigham and Women s Hospital and St Elizabeth s Medical Center, Boston, MA 02115, USA
    Am J Respir Crit Care Med 180:948-55. 2009
    ..Mortality and its causes was a secondary endpoint in UPLIFT...
  7. pmc Use of anticholinergics and the risk of cognitive impairment in an African American population
    N L Campbell
    Wishard Health Services, Indianapolis, IN 46202 2872, USA
    Neurology 75:152-9. 2010
    ..Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment...
  8. ncbi Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial
    T Troosters
    Respiratory Division and Pulmonary Rehabilitation, UZ Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium
    Eur Respir J 36:65-73. 2010
    ..6 units (p<0.001) with tiotropium compared to placebo. In patients with COPD who are not on maintenance therapy, tiotropium is associated with significant benefits in disease progression...
  9. pmc The cognitive impact of anticholinergics: a clinical review
    Noll Campbell
    Wishard Health Services, Indianapolis, IN, USA
    Clin Interv Aging 4:225-33. 2009
    ..However, there has been no systematic confirmation that acute or chronic prescribing of such medications lead to transient or permanent adverse cognitive outcomes...
  10. ncbi Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
    D E O'Donnell
    Respiratory Investigation Unit, Dept of Medicine, Queen s University, Kingston, Ontario, Canada
    Eur Respir J 23:832-40. 2004
    ..Resultant increases in inspiratory capacity permitted greater expansion of tidal volume and contributed to improvements in both exertional dyspnoea and exercise endurance...
  11. ncbi Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease
    Kristen E Belmonte
    Respiratory and Inflammation Centre of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA
    Proc Am Thorac Soc 2:297-304; discussion 311-2. 2005
    ..Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors...
  12. ncbi The anticholinergic risk scale and anticholinergic adverse effects in older persons
    James L Rudolph
    Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, MA 02130, USA
    Arch Intern Med 168:508-13. 2008
    ..The objective of this study was to determine if the ARS score could be used to predict the risk of anticholinergic adverse effects in a geriatric evaluation and management (GEM) cohort and in a primary care cohort...
  13. ncbi Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
    I S T Bos
    Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Eur Respir J 30:653-61. 2007
    ....
  14. ncbi Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, Texas 77030, USA
    Proc Am Thorac Soc 4:526-34. 2007
    ..Several novel bronchodilators are now in different stages of development for use alone or in combination with other agents...
  15. ncbi COPD: management of acute exacerbations and chronic stable disease
    M H Hunter
    Department of Family Medicine, Medical University of South Carolina College of Medicine, Charleston, USA
    Am Fam Physician 64:603-12. 2001
    ..Influenza and pneumococcal vaccines should be given. Patients who do not respond to standard therapies may benefit from surgery...
  16. ncbi Cardiovascular events associated with ipratropium bromide in COPD
    Sarika S Ogale
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
    Chest 137:13-9. 2010
    ..We sought to examine the association between ipratropium bromide use and the risk of cardiovascular events (CVEs)...
  17. ncbi Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA
    Drugs 69:2025-33. 2009
    ..It is possible that the reduction in respiratory morbidity could improve functional status and reduce adverse cardiac outcomes over time. Further studies are needed to address this important issue...
  18. ncbi The role of anticholinergics in chronic obstructive pulmonary disease
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
    Am J Med 117:24S-32S. 2004
    ..Once-daily administration of tiotropium is well tolerated and has shown significant advantages over ipratropium bromide, given 4 times daily, in the control of COPD...
  19. ncbi Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline
    Timothy J Wilt
    Minnesota Agency for Healthcare Research and Quality Evidence based Practice Center, Minneapolis Veterans Affairs Medical Center, and University of Minnesota, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 147:639-53. 2007
    ....
  20. pmc Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study
    Isabelle Carriere
    INSERM, U888, Universite Montpellier 1, Montpellier, France
    Arch Intern Med 169:1317-24. 2009
    ..Despite the high intake of medications with anticholinergic properties by community-dwelling elderly persons, the effects on cognitive decline and dementia have rarely been evaluated...
  21. ncbi How should health-related quality of life be assessed in patients with COPD?
    D A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756 0001, USA
    Chest 117:54S-7S. 2000
    ..Selected studies using disease-specific instruments have demonstrated that beta(2)-agonist, anticholinergic, and theophylline medications can improve HRQOL, as compared with placebo therapy...
  22. ncbi The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity
    Ryan M Carnahan
    University of Oklahoma College of Pharmacy, Department of Pharmacy, Tulsa, Oklahoma 74315 2512, USA
    J Clin Pharmacol 46:1481-6. 2006
    ..This study replicated findings on the association of the ADS with SAA. Future work will determine whether the ADS is clinically useful for preventing anticholinergic adverse effects...
  23. ncbi Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro
    Frank Buhling
    Institute of Immunology, Otto von Guericke University Magdeburg, Magdeburg, Leipziger Str 44, 39120 Magdeburg, Germany
    Respir Med 101:2386-94. 2007
    ..This may contribute to the decreased rate of exacerbations in COPD, which was observed in clinical trials...
  24. ncbi Use of inhaled anticholinergic agents in obstructive airway disease
    Ruben D Restrepo
    Department of Respiratory Care, The University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 6248, San Antonio, TX 78229, USA
    Respir Care 52:833-51. 2007
    ..This article reviews the most current evidence for inhaled anticholinergics in obstructive airway disease and summarizes outcomes reported in randomized controlled trials...
  25. ncbi Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018)
    Xiang Yu Han
    No 7 Department, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, PR China
    Bioorg Med Chem Lett 15:1979-82. 2005
    ..The intramolecular asymmetric epoxidation of mono-sulfonate 4 was applied for the execution of the synthesis of the key chiral building block for the first time. The isomers were obtained with 70-76% yields in 99-100% ee...
  26. pmc Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Gen Intern Med 21:1011-9. 2006
    ..Anticholinergics and beta2-agonists have generally been considered equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD)...
  27. ncbi The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis
    Benedict T Blake-James
    Institute of Urology, University College London, UK
    BJU Int 99:85-96. 2007
    ..To assess the safety and efficacy of anticholinergics in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) by a systematic review of published reports and a meta-analysis of the reported outcomes...
  28. pmc A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
    Daniel E Hilleman
    Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska 68178, USA
    Int J Chron Obstruct Pulmon Dis 4:253-63. 2009
    ..Prospective, adequately powered RCTs are needed to provide more evidence for the CV safety of tiotropium...
  29. ncbi The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern? A review of evidence from clinical trials
    Anees Sindi
    Firestone Institute for Respiratory Health, St Joseph s Healthcare, Canada
    Pol Arch Med Wewn 119:74-8. 2009
    ..This provides the facts surrounding this debate and reinforces our belief in the safety of inhaled anticholinergics...
  30. ncbi Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients
    Carol Paton
    Oxleas NHS Trust, Pinewood House, Dartford, Kent, UK
    J Psychopharmacol 17:223-9. 2003
    ..Antipsychotic prescribing often deviates from recommended practice. Nursing staff have considerable discretion to administer large doses of antipsychotics on an 'as required' basis...
  31. ncbi Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial
    Dennis E Niewoehner
    Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 143:317-26. 2005
    ..Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clinical and health resource use ramifications...
  32. ncbi Anticholinergic agents in asthma and COPD
    Nicholas J Gross
    Stritch Loyola School of Medicine, Voluntary Attending Physician, Hines VA Hospital, Chicago, Hines, IL 60141, USA
    Eur J Pharmacol 533:36-9. 2006
    ..All of the above agents have a wide therapeutic margin and are safe and well tolerated by patients...
  33. ncbi Conservative management in neurogenic bladder dysfunction
    Ahmet R Aslan
    Division of Urology, Albany Medical College, New York 12208, USA
    Curr Opin Urol 12:473-7. 2002
    ..In this article, we will focus on the most recent data on new modalities of therapy to help avoid urinary diversion or bladder augmentation...
  34. ncbi Significant correlation between plasma and CSF anticholinergic activity in presurgical patients
    Konstanze Plaschke
    Department of Anesthesia, Medical Faculty of the University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Neurosci Lett 417:16-20. 2007
    ..When patients receiving or not receiving anticholinergic medication were compared, anticholinergic activity tended to increase in blood and CSF after receiving anticholinergic medication > or =4 weeks (p>0.05)...
  35. ncbi Methods for assessing drug-related anticholinergic activity
    Kelly M Rudd
    Section of Clinical Pharmacology, Department of Pharmaceutical Care Services, Bassett Healthcare, Cooperstown, New York 13326, USA
    Pharmacotherapy 25:1592-601. 2005
    ..Each of the four has merits and limitations, with no ideal evidence-based approach used. Three of the four methods described have research utility; however, only one of the methods is clinically useful...
  36. ncbi Medications for COPD: a review of effectiveness
    Gil C Grimes
    Texas A and M University Health Science Center, Temple, Texas, USA
    Am Fam Physician 76:1141-8. 2007
    ..Patients with severe hypoxemia (i.e., arterial oxygen pressure less than 55 mm Hg or oxygen saturation less than 88 percent) should be given continuous oxygen...
  37. ncbi A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
    R Casaburi
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    Eur Respir J 19:217-24. 2002
    ..This suggests that tiotropium will make an important contribution to chronic obstructive pulmonary disease therapy...
  38. pmc Management of drooling in disabled patients with scopolamine patches
    Abigail Mato
    Special Needs Department, School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain
    Br J Clin Pharmacol 69:684-8. 2010
    ..To evaluate the efficacy of scopolamine administered transdermally for the treatment of drooling in severely disabled patients...
  39. ncbi Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Departments of Medicine and Community Health and Epidemiology, Queen s University, Kingston, Ontario, Canada
    Am J Respir Crit Care Med 160:542-9. 1999
    ..IC should be used in conjunction with FEV(1) when evaluating therapeutic responses in COPD...
  40. ncbi The management of drooling in adults with neurological conditions
    Nina Squires
    Speech and Language Therapy Department, Queen s Medical Centre, Nottingham, UK
    Curr Opin Otolaryngol Head Neck Surg 20:171-6. 2012
    ..This review will consider the physical and psychosocial impact of drooling and will discuss the current management options including behavioural, pharmacological and surgical approaches...
  41. ncbi Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease
    Teri R Thomsen
    Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 22:2268-73. 2007
    ..There were no significant adverse events. Ipratropium bromide spray was well tolerated in subjects with PD. Although it did not affect objective measures of saliva production, further studies in parkinsonism may be warranted...
  42. ncbi Bronchodilator responsiveness in patients with COPD
    D P Tashkin
    David Geffen School of Medicine, UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90024, USA
    Eur Respir J 31:742-50. 2008
    ..The majority of patients with moderate-to-very-severe chronic obstructive pulmonary disease demonstrate meaningful increases in lung function following administration of inhaled anticholinergic plus sympathomimetic bronchodilators...
  43. ncbi Physostigmine: is there a role for this antidote in pediatric poisonings?
    Nan Frascogna
    Division of Pediatric Emergency Medicine, Department of Pediatrics, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35233, USA
    Curr Opin Pediatr 19:201-5. 2007
    ..This paper reviews the anticholinergic toxidrome and pathophysiology, recent literature on the efficacy and toxicity of physostigmine, and its dosing, indications, and contraindications...
  44. ncbi Cardiovascular safety of tiotropium in patients with COPD
    Bartolome Celli
    Carita St Elizabeth s Medical Center, Boston, MA, USA
    Chest 137:20-30. 2010
    ..The clinical trial safety database for tiotropium has been augmented with a 4-year trial in patients with COPD, which provides an opportunity to better evaluate the cardiovascular (CV) profile of tiotropium...
  45. ncbi Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology
    Myrna B Dolovich
    Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
    Chest 127:335-71. 2005
    ..There are advantages and disadvantages associated with each device category. Evidence-based guidelines for the selection of the appropriate aerosol delivery device in specific clinical settings are needed...
  46. pmc Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study
    Marie L Ancelin
    INSERM, E361, Pathologies of the Nervous System, 34093 Montpellier, France
    BMJ 332:455-9. 2006
    ..To assess the potential of anticholinergic drugs as a cause of non-degenerative mild cognitive impairment in elderly people...
  47. ncbi Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: neurochemical mechanisms
    Yong An Wang
    Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, PR China
    Life Sci 78:210-23. 2005
    ....
  48. ncbi Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study
    Juho Uusvaara
    Helsinki University Hospital, Finland
    Drugs Aging 28:131-8. 2011
    ..However, studies of the prognostic implications of DAPs remain scarce...
  49. pmc Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD
    A B Tonnel
    Centre Hospitalier Régional Universitaire CHRU de Lille, Service de Pneumologie et Immuno Allergologie, Lille Cedex, France
    Int J Chron Obstruct Pulmon Dis 3:301-10. 2008
    ..01 +/- 0.02 L; between-group difference: 0.10 +/- 0.03 L, p = 0.0001) and reduced exacerbations vs placebo. Maintenance treatment with tiotropium provided significant and clinically relevant improvements in HRQoL, as measured by the SGRQ...
  50. ncbi Anthelmintic paraherquamides are cholinergic antagonists in gastrointestinal nematodes and mammals
    Erich W Zinser
    Pharmacia Animal Health, Kalamazoo, MI 49001 0019, USA
    J Vet Pharmacol Ther 25:241-50. 2002
    ..the alpha7 CNS subtype. PHQ anthelmintics are nicotinic cholinergic antagonists in both nematodes and mammals, and this mechanism appears to underlie both their efficacy and toxicity.
  51. ncbi Long-term cognitive impact of anticholinergic medications in older adults
    Kara A Bottiggi
    Graduate Center for Gerontology, University of Kentucky, Lexington, KY, USA
    Am J Geriatr Psychiatry 14:980-4. 2006
    ..The objective of this study was to determine whether chronic use of medications with anticholinergic (AC) properties impact older adults' cognitive functioning...
  52. ncbi The participation of the cholinergic system in regulating progesterone secretion through the ovarian-adrenal crosstalk varies along the estrous cycle
    Angelica Flores
    Biology of Reproduction Research Unit, FES Zaragoza, UNAM, Mexico
    Endocrine 28:145-51. 2005
    ....
  53. pmc Optimising treatment for COPD--new strategies for combination therapy
    T Welte
    Department of Respiratory Medicine, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Int J Clin Pract 63:1136-49. 2009
    ....
  54. ncbi Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study
    M Wadbo
    Dept of Respiratory Medicine in Malmö General University Hospital, Malmo, Sweden
    Eur Respir J 20:1138-46. 2002
    ..Formoterol reduced relief medication use compared with placebo. Neither active treatment improved QoL. Formoterol and ipratropium improved airway function and symptoms, without significant improvements in the shuttle walking test...
  55. ncbi Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events
    Jose Ness
    Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52246, USA
    Am J Geriatr Pharmacother 4:42-51. 2006
    ..The burden of drug-related anticholinergic symptoms in community-dwelling elderly patients has not been well described...
  56. ncbi Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder
    K P Junemann
    Department of Urology, University Hospital Kiel, Kiel, Germany
    Urol Int 77:334-9. 2006
    ..The primary outcome measure is incontinence episode frequency, with secondary outcome measures including mean volume per void and quality of life as assessed on King's Health Questionnaire...
  57. pmc The acute asymmetric effects of hemiovariectomy on testosterone secretion vary along the estrous cycle. The participation of the cholinergic system
    Angelica Flores
    Biology of Reproduction Research Unit, FES Zaragoza, UNAM, Mexico
    Reprod Biol Endocrinol 4:11. 2006
    ..The results presented herein support the hypothesis of asymmetry in the ovaries' abilities to secrete steroid hormones, and that the capacity to secrete testosterone varies along the estrous cycle...
  58. ncbi Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial
    D P Tashkin
    Dept of Medicine, David Geffen School of Medicine, UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 1690, USA
    Eur Respir J 35:287-94. 2010
    ..63 units, p = 0.0006) and the least in IS (-0.60 units, p = 0.51), [corrected] compared with control. Tiotropium provided long-term benefits irrespective of smoking status, although differences among categories were observed...
  59. pmc Tiotropium HandiHaler in the treatment of COPD: a safety review
    Steven Kesten
    Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT 06877 0368, USA
    Int J Chron Obstruct Pulmon Dis 4:397-409. 2009
    ..We sought to update an evaluation of the safety of tiotropium in the HandiHaler formulation as significant clinical trial data have become available over time...
  60. ncbi Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling
    Reinoud Gosens
    Department of Molecular Pharmacology, University Centre for Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Am J Respir Crit Care Med 171:1096-102. 2005
    ....
  61. ncbi Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Pulm Pharmacol Ther 18:1-8. 2005
    ..Finally, a number of novel targets for the treatment of airway mucociliary dysfunction have been identified, and targeting agents are currently in development...
  62. ncbi Tiotropium bromide
    Nicholas J Gross
    Hines VA Hospital, PO Box 1485, Hines, IL 60141, USA
    Chest 126:1946-53. 2004
    ..Several 1-year studies demonstrate that the only significant side effect of tiotropium was dryness of the mouth, which occurred in approximately 10 to 16% of patients; it is well tolerated by patients and safe...
  63. ncbi Delirium in acute stroke: a preliminary study of the role of anticholinergic medications
    L Caeiro
    Servico de Neurologia, Stroke Unit, Hospital de Santa Maria, Faculdade de Medicina de Lisboa, Portugal
    Eur J Neurol 11:699-704. 2004
    ..This preliminary result indicates that drugs with subtle ACH activity play a role in the pathogeneses of delirium in acute stroke. Medication with ACH activity should be avoided in acute stroke patients...
  64. ncbi Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD)
    Mitchell Friedman
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Pharmacoeconomics 22:741-9. 2004
    ....
  65. ncbi Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD
    W T McNicholas
    Dept of Respiratory Medicine, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Eur Respir J 23:825-31. 2004
    ..End-of-treatment FEV1 correlated with Sa,O2 during REM sleep, however, tiotropium did not change sleep quality. Sustained anticholinergic blockade improves sleeping arterial oxygen saturation without affecting sleep quality...
  66. ncbi Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians
    Amir Qaseem
    American College of Physicians and Drexel University College of Medicine, Philadelphia, Pennsylvania 19106, USA
    Ann Intern Med 147:633-8. 2007
    ..RECOMMENDATION 6: Clinicians should consider prescribing pulmonary rehabilitation in symptomatic individuals with COPD who have an FEV1 less than 50% predicted. (Grade: weak recommendation, moderate-quality evidence.)...
  67. ncbi Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD
    Richard Casaburi
    Division of Respiratory and Critical Care Physiology and Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Building RB 2, Torrance, CA 90502, USA
    Chest 127:809-17. 2005
    ..We hypothesized that ventilatory mechanics improvements from tiotropium would permit enhanced ability to train muscles of ambulation and therefore augment exercise tolerance benefits of PR...
  68. ncbi Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications
    Rita D Jewart
    Department of Psychiatry, Emory University School of Medicine, Wesley Woods Health Center, 1841 Clifton Road NE, Atlanta, GA 30329, USA
    Am J Geriatr Psychiatry 13:324-8. 2005
    ..Authors evaluated the cognitive, neurophysiologic, and behavioral effects of incontinence medications in patients with Alzheimer disease (AD)...
  69. ncbi Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Clin Rev Allergy Immunol 31:219-30. 2006
    ..beta-Agonists increase respiratory deaths in COPD, possibly as a result of poorer disease control...
  70. ncbi EEG changes and serum anticholinergic activity measured in patients with delirium in the intensive care unit
    K Plaschke
    Department of Anaesthesiology, Medical Faculty of the University of Heidelberg, Germany
    Anaesthesia 62:1217-23. 2007
    ..We conclude that, in contrast to the EEG, the SAA level cannot be proposed as a tool for diagnosing delirium in ICU patients...
  71. ncbi Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease
    Gerard J Criner
    Temple University School of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
    COPD 5:35-41. 2008
    ..In patients of African descent, possible differences have been observed for inhaled beta-agonists. However, pharmacologic responsiveness to a long-acting anticholinergic has not been prospectively evaluated...
  72. ncbi Therapeutic gains of prolonged bronchial dilatation in chronic obstructive pulmonary disease
    Gerard M Turino
    Ann Intern Med 143:386-7. 2005
  73. ncbi Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
    Sonal Singh
    Department of Medicine, One Medical Center Blvd, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    JAMA 300:1439-50. 2008
    ..Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the risk of cardiovascular outcomes is unknown...
  74. ncbi Assessment of pharmacological toxicity using serum anticholinergic activity in a patient with dementia
    Koji Hori
    Psychiatry Clin Neurosci 59:508-10. 2005
  75. ncbi Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia
    Marci L Chew
    Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213, USA
    Am J Geriatr Psychiatry 13:535-8. 2005
    ..The authors investigated the association between serum anticholinergic activity (SAA) and cognitive performance in a group of patients with moderate-to-severe dementia...
  76. pmc Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance
    Nicolino Ambrosino
    Cardio Thoracic Department, University Hospital, Pisa, Italy
    Int J Chron Obstruct Pulmon Dis 3:771-80. 2008
    ..Tiotropium 18 microg once daily induces sustained bronchodilation throughout the day and reduces hyperinflation, one of the pathophysiological factors contributing to exertional dyspnea in COPD patients...
  77. ncbi Management of chronic obstructive pulmonary disease
    R Graham Barr
    JAMA 291:1066-7; author reply 1067. 2004
  78. ncbi The Effects of L-glucose on memory in mice are modulated by peripherally acting cholinergic drugs
    Catherine J Lawson
    Department of Psychology, Macquarie University, Sydney, 2109 Australia
    Neurobiol Learn Mem 77:17-28. 2002
    ..L-Glucose did not facilitate performance on either task when it was simultaneously administered with cholinergic antagonists that are excluded from the central nervous system...
  79. ncbi Contemporary management of chronic obstructive pulmonary disease: scientific review
    Don D Sin
    Division of Pulmonary Medicine, University of Alberta, Edmonton, Canada
    JAMA 290:2301-12. 2003
    ..The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course...
  80. pmc Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease
    P M A Calverley
    Department of Medicine, University of Liverpool, Liverpool, UK
    Thorax 58:855-60. 2003
    ..We hypothesised that tiotropium would modify the overnight change in FEV1, and this would be unaffected by the timing of drug administration...
  81. ncbi Delirium in psychiatric inpatients: a case-control study
    S B Patten
    Departments of Community Health Sciences and Psychiatry, University of Calgary, Calgary, Alberta
    Can J Psychiatry 46:162-6. 2001
    ..To investigate the clinical and pharmacoepidemiological determinants of delirium in a psychiatric inpatient population...
  82. ncbi Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease
    S I Rennard
    University of Nebraska Medical Center, Omaha, Nebraska, USA
    Am J Respir Crit Care Med 163:1087-92. 2001
    ..The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium...
  83. ncbi Endogenous anticholinergic substances may exist during acute illness in elderly medical patients
    J M Flacker
    The Hebrew Rehabilitation Center for Aged Research and Training Institute, Boston, Massachusetts, USA
    J Gerontol A Biol Sci Med Sci 56:M353-5. 2001
    ..The purpose of this study was to determine if serum anticholinergic activity (SACA) arises from endogenous substances produced during illness...
  84. ncbi Anticholinergic effects of medication in elderly patients
    L E Tune
    Division of Geriatric Psychiatry, Wesley Woods Center on Aging, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 62:11-4. 2001
    ..The management of elderly patients, particularly those suffering from dementia, should therefore aim to reduce the use of medications with anticholinergic effects...
  85. ncbi Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses
    Donald Tashkin
    Pulmonary Division, David Geffen School of Medicine at the University of California at Los Angeles, 90095, USA
    Chest 123:1441-9. 2003
    ....
  86. ncbi Tiotropium in the management of chronic obstructive pulmonary disease
    P J Rees
    Eur Respir J 19:205-6. 2002
  87. ncbi Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
    W Vincken
    Respiratory Division, AZ VUB Academic Hospital University of Brussels, Belgium
    Eur Respir J 19:209-16. 2002
    ..The data support the use of tiotropium once-daily as first-line maintenance treatment in patients with chronic obstructive pulmonary disease...
  88. ncbi Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medical Centre, Heerlen, The Netherlands
    Eur Respir J 19:639-44. 2002
    ..The continued increases in forced vital capacity beyond 48 h suggests that maintenance bronchodilator therapy is required to achieve maximal changes in hyperinflation...
  89. ncbi The role of anticholinergics in acute asthma treatment: an evidence-based evaluation
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay
    Chest 121:1977-87. 2002
    ..In patients with mild-to-moderate acute asthma, there is no apparent benefit from adding a single dose of an anticholinergic medication...
  90. ncbi Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance
    Benoit H Mulsant
    Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
    Arch Gen Psychiatry 60:198-203. 2003
    ..To our knowledge, there has not yet been any systematic study of the prevalence of SAA and its effect on cognition in a community-based population...
  91. ncbi The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group
    R Casaburi
    Harbor UCLA Research and Education Institute Dr Casaburi, Torrance, CA 90509, USA
    Chest 118:1294-302. 2000
    ..To compare the bronchodilator efficacy and safety of tiotropium and placebo...
  92. ncbi Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes
    Bartolome Celli
    Pulmonary and Critical Care Division, St Elizabeth s Medical Center, Boston, MA 02135, USA
    Chest 124:1743-8. 2003
    ..We sought to evaluate changes in resting IC and lung volumes after long-term administration of tiotropium...
  93. ncbi Serum anticholinergic activity changes with acute illness in elderly medical patients
    J M Flacker
    Hebrew Rehabilitation Center for Aged Research and Training Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Gerontol A Biol Sci Med Sci 54:M12-6. 1999
    ..This study used serial measures of serum anticholinergic activity levels to determine whether these levels change following illness resolution, and if such changes are specific to those with delirium...
  94. ncbi Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD
    R J Martin
    National Jewish Medical and Research Center, Denver, CO 80206, USA
    Chest 115:1338-45. 1999
    ..Therefore, we investigated whether 4-week treatment with ipratropium bromide inhalation solution 0.02% (qid) could improve sleep characteristics in COPD...
  95. ncbi Association of anticholinergic load with impairment of complex attention and memory in schizophrenia
    Michael J Minzenberg
    Department of Psychiatry, Mount Sinai School of Medicine and VA Medical Center, Bronx, NY, USA
    Am J Psychiatry 161:116-24. 2004
    ....
  96. ncbi The role of long-acting bronchodilators in the management of stable COPD
    Donald P Tashkin
    Division of Pulmonary and Critical Care Medicine and the UCLA Pulmonary Function and Exercise Physiology Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1690, USA
    Chest 125:249-59. 2004
    ..Based on this review, a treatment algorithm for the introduction of long-acting bronchodilators to patients with COPD is proposed, which includes the use of long-acting bronchodilators early in the treatment algorithm...
  97. ncbi Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children
    P Amark
    Department of Pediatrics, Karolinska Hospital, Stockholm, Sweden
    Eur Urol 34:148-53. 1998
    ..Recently, the use of oxybutynin, a compound with anticholinergic, smooth muscle relaxant and local anesthetic effects, has become widely used with both oral and intravesical administration...
  98. pmc Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Int J Chron Obstruct Pulmon Dis 2:11-8. 2007
    ..These results indicate that anticholinergics should be the bronchodilator of choice in COPD, while beta-agonists may be associated with poorer disease control...
  99. ncbi [Practice guideline 'Medical treatment of COPD']
    P N R Dekhuijzen
    Universitair Medisch Centrum St Radboud, afd Longziekten, 454, Postbus 9101, 6500 HB Nijmegen
    Ned Tijdschr Geneeskd 152:1465-8. 2008
    ....
  100. ncbi [COPD treatment by drugs]
    S Nafti
    Clinique des Maladies Respiratoires, hôpital Mustapha, CHU Alger Centre 16000 Alger, Algerie
    Rev Mal Respir 23:10S58-10S60. 2006
  101. ncbi The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease
    Kenneth R Chapman
    Toronto Western Hospital, Ontario
    Can Respir J 9:178-85. 2002
    ..In the past, the role of long-acting beta(2-) agonists in chronic obstructive pulmonary disease (COPD) relative to other agents has been unclear...

Research Grants64

  1. Pharmacological Management of Delirium
    Malaz Boustani; Fiscal Year: 2013
    ..The primary outcomes of the study are delirium severity, as measured by the Delirium Rating Scale (DRS-R-98);and delirium duration as measured by the Confusion Assessment Method in the ICU (CAM-ICU). ..
  2. M1 and M4 mAChRs in striatum-implication in treatment of movement disorders
    Zixiu Xiang; Fiscal Year: 2013
    ....
  3. Anticholinergics and Cognitive Decline in the Elderly with Depression
    Rajender R Aparasu; Fiscal Year: 2013
    ....
  4. Estrogen Effects on Cholinergic Function in Older Women
    Paul A Newhouse; Fiscal Year: 2013
    ..g. neuroimaging). The over arching goal is to develop information to allow the development of models to potentially predict which women may benefit from the cognitive effects of estradiol after menopause. ..
  5. Characterizing and Predicting Drug Effects on Cognition
    SUSAN E MARINO; Fiscal Year: 2013
    ..Future directions will extend this approach to patients across different disorders (e.g., epilepsy, Alzheimer's) and multiple drug classes (e.g., anticholinergics, antipsychotics). ..
  6. URGE
    Jennifer Marie Wu; Fiscal Year: 2013
    ..Furthermore, this pioneering pharmacogenetic research has the potential to lay essential groundwork for future long-term research which would optimize and personalize UUI therapy for millions of elderly women. ..
  7. DOPAMINE RECEPTOR SUBTYPES & FUNCTION
    Emanuel Meller; Fiscal Year: 1993
    ..2) Cholinergic antagonists (e.g...
  8. Effect of anticholinergic drugs &white matter hyperintensities on balance &gait
    Robert D Nebes; Fiscal Year: 2012
    ..If the proposed studies show that anticholinergic medications are associated with balance and gait problems, then reducing usage of these medications could lessen the mobility limitations present in many older persons ..
  9. REGULATION OF PANCREATIC MUSCARINIC RECEPTORS IN VITRO
    SETH HOOTMAN; Fiscal Year: 1990
    ..The proposed studies will address fundamental questions regarding the mechanisms by which exocrine gland secretory cells adjust to varying intensity and duration of neurohumoral stimulation...
  10. NEW MUSCARINIC AGENTS--SELECTIVITY OF ACTION
    Frank Carroll; Fiscal Year: 1990
    ..The development of new, more effective, selective and less toxic cholinergic and anticholinergic drugs is of interest due to the possible therapeutic exploitation of the cholinergic hypothesis of Alzheimer's disease...
  11. Psychoactive Medications: Associations with Delirium Persistance vs Resolution
    Edward Marcantonio; Fiscal Year: 2009
    ..resolution of delirium. Our results will inform the medication management of delirium and the design of specific evidence-based interventions to treat delirium and improve functional recovery in both acute and post-acute care settings. ..
  12. Airway Eosinophil Activation by Anticholinergic Therapy
    David Jacoby; Fiscal Year: 2009
    ..In this project, we will find out how these drugs are making the asthma worse and, in so doing, find out how to design a treatment that won't have these negative effects. ..
  13. CHOLINERGIC PHARMACOLOGY OF BASAL FOREBRAIN NEURONS
    Susan Robinson; Fiscal Year: 1990
    ..postsynaptic cholinergic receptors so that cholinergic neurotransmission can be effectively enhanced by cholinergic antagonists which block presynaptic receptors but not postsynaptic receptors...
  14. SYNAPTIC ORGANIZATION OF BASAL FOREBRAIN PROJECTIONS
    David Finch; Fiscal Year: 1991
    ..effect of stimulation will be compared to the action of the cholinergic agonists, and the efficacy of the cholinergic antagonists in blocking the evoked synaptic will be determined...
  15. LIMBIC SENSITIVITY IN COCAINE ADDICTION
    Bryon Adinoff; Fiscal Year: 2005
    ..Our competing renewal will be used to identify specific changes in these neuroreceptor systems, providing avenues for new pharmacologic investigations in the treatment of cocaine dependence. ..
  16. NEOSTRIATAL CHOLINERGIC INTERNEURONS FIRING PATTERNS
    Charles J Wilson; Fiscal Year: 2010
    ..The observation that cholinergic antagonists are clinically effective in treating Parkinson's disease has led many investigators to suggest that ..
  17. Estrogenic-cholinergic interactions in memory modulation
    KARYN FRICK; Fiscal Year: 2004
    ..abstract_text> ..
  18. Hypocretin agonists as treatments for narcolepsy and wakefulness promotion
    THOMAS KILDUFF; Fiscal Year: 2009
    ....
  19. Cognitive, Pharmacological and fMRI Studies of Memory
    CHANTAL STERN; Fiscal Year: 2004
    ....
  20. MDMA Neurotoxicity in Humans: Occurence & Consequences
    George Ricaurte; Fiscal Year: 2006
    ....
  21. CHROMOGRANIN A--NICOTINIC SIGNALING AND DESENSITIZATION
    Sushil Mahata; Fiscal Year: 2001
    ....
  22. NEUROPHARMACOLOGIC CHALLENGES IN DEMENTIA
    Norman Foster; Fiscal Year: 1992
    ..A better understanding of the cognitive effects of glutamatergic antagonists will also be useful when considering whether these drugs ought to be used to treat neurological disorders...
  23. DRUG-INDUCED MOVEMENT DISORDERS IN SCHIZOPHRENIA
    William Hoffman; Fiscal Year: 1991
    ....
  24. REGULATION OF NEURAL ACETYLCHOLINE RECEPTORS
    Norman Boyd; Fiscal Year: 1991
    ..will be examined by kinetic analysis of the effects on the rates of each of these processes by different cholinergic antagonists. The role of other synaptic components both extracellular, e.g. substance P, and intracellular, e.g...
  25. Effect of Daily Exercise on Cardiac Autonomic Regulation
    GEORGE BILLMAN; Fiscal Year: 2005
    ..Ventricular contractile responses to Beta1- and Beta2-adrenoceptor stimulation will be examined in vivo by echocardiography and in vitro by single cell fluorescence microscopy/video edge detection. ..
  26. BIOGENIC AMINE/DRUG EFFECTS ON CNS RECEPTOR
    ROBERT FRIEDEL; Fiscal Year: 1980
    ..on phospholipid metabolism of the rat corpus striatum, to determine potency of inhibition of a variety of cholinergic antagonists on these effects, and to determine the presence or absence of cholinergic antagonism of neuroleptic ..
  27. Nicotinic Cholinergic Receptors and Cocaine Reward
    STEPHEN HANSEN; Fiscal Year: 2006
    ..The proposed experiments will determine the ability of cholinergic antagonists to modulate cocaine self-administration behavior in rats...
  28. Intrastriatal cholinergic modulation of learning
    WAYNE PRATT; Fiscal Year: 2005
    ..These experiments should increase the understanding of the role of striatal muscarinic acetylcholine processes underlying learning, and its interactions with dopamine. ..
  29. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  30. SCLERODERMA LUNG STUDY
    Donald Tashkin; Fiscal Year: 2003
    ..abstract_text> ..
  31. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  32. AGING, WHITE MATTER HYPERINTENSITIES & COGNITIVE DECLINE
    Robert Nebes; Fiscal Year: 2001
    ....
  33. Strategies to Improve COPD Management
    Richard Casaburi; Fiscal Year: 2007
    ..These studies should have immediate impact on treatment strategies for large poor-prognosis subgroups of COPD patients. ..
  34. Anticholinergic Drugs, Cognitive Deficits & Normal Aging
    Robert Nebes; Fiscal Year: 2006
    ..We will also examine whether the decrements that anticholinergic drugs produce in higher-level cognitive abilities are mediated through decreases in working memory, processing speed or inhibitory efficiency. ..
  35. Adolescence: A Sensitive Period for Nicotine Addiction
    Edward Levin; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  36. Behavioral Genetics and Toxic Response
    Edward Levin; Fiscal Year: 2002
    ....
  37. HEAD CONTROL MECHANISMS DURING VOLUNTARY TRUNK MOVEMENTS
    Timothy Hain; Fiscal Year: 2002
    ..The comparison of intact and BVL populations will elucidate why some persons with BVL recover relatively high functional levels, and others do not. ..
  38. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2008
    ..abstract_text> ..
  39. Nicotinic-Antipsychotic Drug Interactions and Cognition
    Edward Levin; Fiscal Year: 2006
    ..abstract_text> ..
  40. LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
    Nunzio Pomara; Fiscal Year: 2005
    ..index of brain white matter organization) contribute most strongly to the acute effects of lorazepam on cognitive/motor performance or postural sway in elderly individuals receiving long-term lorazepam treatment for GAD? ..
  41. Optotrack Motion Analysis System
    Timothy Hain; Fiscal Year: 2005
    ..Motion analysis equipment is critical to all of our research faculty, and we have also recently added investigators to the department who need motion analysis capabilities. ..
  42. V & Q Disturbances in Obliterative Bronchiolitis
    David Lipson; Fiscal Year: 2005
    ..abstract_text> ..
  43. Marine Toxin Impacts on Neurobehavioral Function
    Edward Levin; Fiscal Year: 2003
    ..The forum will provide an opportunity for methodological and theoretical issues to be integrated in the context of each talk as well as in a discussion session at the end of the symposium. ..
  44. Cholinergic modulation of odor responses
    Christiane Linster; Fiscal Year: 2003
    ..The cholinergic nature of the observed effects will be tested by injection of cholinergic antagonists (muscarinic and/or nicotinic)...
  45. BENZODIAZEPINE USE AND RISK OF DISABILITY IN THE ELDERLY
    Shelly Gray; Fiscal Year: 2003
    ....
  46. Cholinergic modulation of IEG expression
    ANN POWER; Fiscal Year: 2006
    ..Experiment III will investigate which signaling cascades (e.g., protein kinases) are involved in effects of mR activation on memory and immediate early gene expression. ..
  47. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  48. Mechanisms of Disability in Peripheral Arterial Disease
    Mary McDermott; Fiscal Year: 2005
    ..Results will be used to develop interventions designed to improve lower extremity functioning and prevent functional decline in persons with PAD. ..
  49. NEUROBIOLOGICAL EFFECTS OF ALTERED MOTOR CONTROL IN REM
    LARRY SANFORD; Fiscal Year: 2001
    ..These studies may lead to a better understanding of disorders of REM, such as REM behavior disorder, which, like REM-A, is characterized by overt behavior during sleep. ..
  50. NEUROLEPTIC-INDUCED MOVEMENT DISORDERS IN OLDER PATIENTS
    Dilip Jeste; Fiscal Year: 2003
    ..We believe that our findings will have major therapeutic implications for the use of antipsychotics, particularly in older patients. ..
  51. PHENOTYPICAL EXPRESSION OF ANXIETY AND SLEEP
    LARRY SANFORD; Fiscal Year: 2009
    ....
  52. CAREER LEADERSHIP AWARD
    Joseph Ouslander; Fiscal Year: 2004
    ..The outcomes of each specific aim will be carefully tracked and evaluated utilizing a number of quantitative measures. ..
  53. NIH Task Force on Childhood Motor Disorders
    Terence Sanger; Fiscal Year: 2006
    ..The ultimate objective is to improve the functional abilities and societal participation of children with motor disorders. ..
  54. CENTER FOR RESEARCH IN OLDER PEOPLE WITH PSYCHOSES
    Dilip Jeste; Fiscal Year: 2006
    ....
  55. BLOOD FACTORS AND PERIPHERAL ARTERIAL DISEASE OUTCOMES
    Mary McDermott; Fiscal Year: 2004
    ....
  56. Beta-2 Receptor Polymorphisms and Vasodilation in Humans
    John Eisenach; Fiscal Year: 2007
    ..My long-term career goal is to become an independent investigator performing physiology and pharmacology studies directed at the genomics of the cardiovascular system in humans. ..
  57. Gene-Specific Responses to Exercise in Discordant Twins
    Paul Williams; Fiscal Year: 2007
    ..DNA samples will be shared with other institutions to cross-validate gene associations identified from training studies or other designs. ..
  58. The dynamics of rapsyn in vitro and in vivo
    Emile Bruneau; Fiscal Year: 2007
    ..By investigating the behavior of these proteins we may therefore be able to define new avenues for the development of therapies for neuromuscular disease. [unreadable] [unreadable]..
  59. Innovative Investigations and Therapies for Asthma
    Richard Martin; Fiscal Year: 2007
    ..The ability to predict who will and will not respond to corticosteroids and additive therapy will greatly improve our ability to treat asthma effectively. ..
  60. Effects of Opioid Pharmacotherapy on Functioning
    MIRIAM MINTZER; Fiscal Year: 2008
    ..Data from this project may also enhance the scientific understanding of pharmacological and cognitive mechanisms. ..
  61. Enhancing Care for Hospitalized Older Adults with CI
    Malaz Boustani; Fiscal Year: 2008
    ..abstract_text> ..
  62. Combined Chemoprevention Using a Nanotechnology-based Therapeutic System
    Sunil Prabhu; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  63. Pneumografting - a novel cell-based therapy for emphysema
    Edward P Ingenito; Fiscal Year: 2010
    ..We intend to advance this approach, known as pneumografting, into human trials under a physician-sponsored Investigation New Drug Application. ..